AcelRx Pharmaceuticals has commenced with its IAP312 Phase 3 trial for the study of Zalviso, its new investigational product in development to treat moderate-to-severe acute pain in adult hospital patients. Read More »

Corvus Pharmaceuticals has released the preclinical data and preclinical biomarker data from its Phase 1/1b CPI-444 clinical study. Read More »

H. Lundbeck and Otsuka Pharmaceutical Development & Commercialization have reported that the U.S. Food and Drug Administration has approved the update to the Rexulti label. Read More »

Ajanta Pharma USA has made Omeprazole and Sodium Bicarbonate Powder for Oral Suspension available in the United States. Read More »

The U.S. Food and Drug Administration has approved Amgen’s AMJEVITA for the treatment of seven different inflammatory diseases. Read More »

Mucodel Pharma, a private company based in Greensboro, North Carolina, that is dedicated to the development of improved rescue therapies to be administered oromucosally, has completed its Exonal (buccal naloxone) clinical study. Read More »

Pacira Pharmaceuticals has released new data supporting EXPAREL and the benefits it could offer patients who must undergo third molar, or wisdom teeth, removal. Read More »

Epizyme Inc. has agreed to a partnership with Foundation Medicine to identify and enroll support patients for the upcoming Phase 2 trial of tazemetostat on patients who have non-Hodgkin lymphoma. Read More »

The U.S. Food and Drug Administration has approved Bayer's progestin-containing intrauternine system Kyleena for pregnancy prevention for a span of up to five years. Read More »

Diffusion Pharmaceuticals has completed the dosing of two animal toxicology studies that are required by the U.S. Food and Drug Administration for approval of Diffusion’s lead molecule trans sodium crocetinate Phase 3 trial. Read More »

Vical Inc. and Astellas Pharma's Phase 2 study of cytomegalovirus vaccine ASP0113 has achieved topline results. Read More »

Corvus Pharmaceuticals presented preclinical data from its Phase1/1b study of CPI-444, and preliminary biomarker data from the trial.  Read More »

Elusys Therapeutics has published data from five clinical trials of ANTHIM, which was used to support the marketing approval by the U.S. Food and Drug Administration.  Read More »

Apintyx Inc. will develop its lead compound, NYX-2925, to treat neuropathic pain linked to diabetic peripheral neuropathy. Read More »

Avara Pharmaceutical Services Inc. recently celebrated the one-year anniversary of its purchase of the Arecibo site in Puerto Rico from Merck. Read More »

CVS Health reported this week that it has increased access to naloxone, the opioid overdose-reversal medication, to include five new states — Alabama, Alaska, Illinois, Missouri and West Virginia. Read More »

AbbVie recently announced that the small molecule active pharmaceutical ingredient (API) facility constructed at its Singapore manufacturing site is now open. Read More »

Allergan Inc. recently announced the acquisition of Akarna Therapeutics for an upfront payment of $50 million.   Read More »

Abbott announced this week that its FreeStyle Libre Pro system, a groundbreaking continuous glucose monitoring (CGM) system designed for patients with diabetes, has been approved by the U.S. Food and Drug Administration (FDA).re Read More »

Perrigo Co. this week announced that it has agreed to an exclusive licensing agreement with Highland Pharmaceuticals LLC for its methamphetamine (meth) blocking technology called Tarex. Read More »